Cantor Fitzgerald Lowers Earnings Estimates for Cybin

Cybin Inc. (OTCMKTS:CYBN) – Cantor Fitzgerald decreased their FY2026 earnings per share estimates for Cybin in a report released on Wednesday, November 5th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($3.08) per share for the year, down from their previous estimate of ($2.77). The consensus estimate for Cybin’s current full-year earnings is ($0.19) per share.

Cybin Stock Down 2.1%

Shares of Cybin stock traded down $0.13 during trading hours on Friday, reaching $5.94. 259,866 shares of the company’s stock were exchanged, compared to its average volume of 453,231. The company has a market capitalization of $149.62 million, a P/E ratio of -31.26 and a beta of 0.66. Cybin has a 1 year low of $4.81 and a 1 year high of $13.88. The business has a fifty day moving average of $6.27 and a two-hundred day moving average of $7.11.

Institutional Trading of Cybin

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mayflower Financial Advisors LLC purchased a new position in Cybin during the third quarter worth about $60,000. Lewis Asset Management LLC purchased a new position in shares of Cybin during the third quarter worth $82,000. Finally, AdvisorShares Investments LLC boosted its holdings in Cybin by 31.4% during the 3rd quarter. AdvisorShares Investments LLC now owns 116,102 shares of the company’s stock valued at $684,000 after acquiring an additional 27,719 shares during the period. 17.94% of the stock is owned by institutional investors and hedge funds.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.